Streetbeat News

Products Services

CING

Cingulate Inc. (NASDAQ:CING) has successfully manufactured the clinical supply for upcoming pivotal Phase 3 trials of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of attention deficit/hyperactivity disorder (ADHD). The trials are set to begin in July and August. The company recently completed a Phase 3 adult onset and duration study of CTx-1301 with results expected in 3Q 2023. If the trials are successful, Cingulate plans to submit a New Drug Application (NDA) for CTx-1301 in mid-2024.

Portfolio Pulse from Happy Mohamed

June 29, 2023 | 12:17 pm

CEG

MSFT

Constellation (NASDAQ:CEG) has signed an agreement with Microsoft (NASDAQ:MSFT) to reduce the carbon footprint of one of Microsoft's data centers in Virginia. The data center will receive up to 35% in environmental attributes from nuclear power, complementing Microsoft's new wind and solar purchases. Microsoft will track its performance using Constellation's hourly carbon-free energy (CFE) matching platform, a new retail product offering that leverages software technology to help customers achieve their environmental goals.

Portfolio Pulse from Happy Mohamed

June 29, 2023 | 12:14 pm

PYPD

PolyPid has announced a new publication that highlights the antibacterial activity of D-PLEX against susceptible and resistant bacteria for the prevention of surgical site infections. The publication shows the potent antibacterial efficacy of D-PLEX100 in in-vivo and phase 2 clinical studies against a wide range of bacteria tested, including resistant strains.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 12:13 pm

LUMN

CenturyLink Intellectual Property LLC has filed a patent application #20230208891 for an in-line, in-call AI virtual assistant for teleconferencing. The patent application is publicly available for review.

Portfolio Pulse from Charles Gross

June 29, 2023 | 12:12 pm

AKBA

Akebia Therapeutics, Inc. (NASDAQ:AKBA) has announced the top-line results from its Phase 4 IMPACT study of Auryxia, a primary phosphate-lowering therapy for adult patients with chronic kidney disease (CKD) on dialysis. The study, sponsored by U.S. Renal Care Kidney Research in collaboration with Akebia, showed a statistically significant difference in mean monthly erythropoiesis-stimulating agent (ESA) use and a non-significant difference in mean monthly intravenous (IV) iron use. Serious adverse events occurred in 39% of patients receiving Auryxia and 59% in those receiving standard of care (SOC).

Portfolio Pulse from Happy Mohamed

June 29, 2023 | 12:12 pm

EIGR

Eiger BioPharmaceuticals announced its decision to focus on advancing Avexitide in hyperinsulinemic hypoglycemia indications. The company will also explore strategic partnering options in late-stage virology programs and reduce its workforce by 25%.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 12:11 pm

SGMO

VYGR

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) and Voyager Therapeutics, Inc. (NASDAQ:VYGR) have entered into a definitive license agreement for a potential treatment of prion disease. Sangamo has developed zinc finger transcriptional regulators (ZF-TRs) which can block expression of the prion protein. Voyager has provided Sangamo with access to a capsid derived from Voyager's proprietary TRACER™ platform.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 12:06 pm

ENPH

Enphase Energy has expanded its relationship with 4blue to distribute IQ Microinverters and IQ Batteries in the Netherlands, Germany, Belgium, and Luxembourg.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 12:06 pm

FBIO

Urica Therapeutics has announced topline data from its Phase 1 clinical trial of Dotinurad in healthy volunteers in the U.S. The data shows comparable pharmacokinetic, pharmacodynamic, and safety profiles between U.S. and Japanese healthy subjects. The company is initiating a Phase 1b clinical trial in gout patients in the U.S. and expects to begin pivotal clinical trials in 2024.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 12:04 pm